Led by Mr. Supreet Singh, Founder and CEO, and Mr. Jagdeep Singh, Co-Founder and Managing Director, PCHPL has garnered multiple accolades, including two prestigious MSME Business Awards, underscoring its relentless pursuit of delivering high-quality healthcare medicines. This commitment to excellence is further underscored by the company's impressive growth rate, which exceeded 100% during the fiscal year 2022-23, marking a significant leap from previous years.
New Delhi (India), May 14: Psychocare Health Private Limited (PCHPL) has carved a niche for itself in the pharmaceutical landscape by exemplifying an unwavering dedication to quality assurance. Since its inception as the brand "Psychocare" in 2013, and subsequent incorporation in 2018, PCHPL has consistently raised the bar for excellence in the industry.
Led by Mr. Supreet Singh, Founder and CEO, and Mr. Jagdeep Singh, Co-Founder and Managing Director, PCHPL has garnered multiple accolades, including two prestigious MSME Business Awards, underscoring its relentless pursuit of delivering high-quality healthcare medicines. This commitment to excellence is further underscored by the company's impressive growth rate, which exceeded 100% during the fiscal year 2022-23, marking a significant leap from previous years.
At the heart of PCHPL's success lies its comprehensive portfolio of over 900 products spread across four divisions and five sister concerns. These offerings encompass a wide spectrum of therapeutic areas, including neuro/psychiatric, cardio-diabetic, antidepressants, antibiotics, pulmonary, hepatic, urology, orthopedic, dermatological, ayurvedic, health supplements, OTC, and child care products. Each product undergoes stringent quality assessments in adherence to the Good Manufacturing Practices (GMP) and World Health Organization (WHO) standards, ensuring efficacy and reliability nationwide.
Central to PCHPL's operations is its state-of-the-art manufacturing facility, JIPS Pharmaceuticals Private Limited, which is WHO-compliant and GMP-certified. With over 750 approvals in the "Non-Beta Lactam" category for tablets and capsules, the facility epitomizes the company's commitment to producing pharmaceuticals of the highest quality.
Furthermore, PCHPL's foray into e-commerce with www.sehatokart.com reflects its dedication to meeting consumer needs with convenience. By facilitating the seamless delivery of health and skincare products directly to consumers' doorsteps, PCHPL continues to redefine accessibility in the healthcare industry.
Looking ahead, PCHPL is poised for global expansion under the new identity of CancareInc., positioning itself as an E-Commerce Healthcare Company specializing in Natural Health Products (NHP), Ayurveda/Siddha/Unani, and skincare solutions. The recent Master Collaboration Agreement with Novo Integrated Sciences, Inc. (NASDAQ: NVOS) signifies a strategic move to introduce innovative healthcare solutions to the Indian market, further solidifying PCHPL's position as a trailblazer in the pharmaceutical landscape.
PCHPL's unwavering commitment to quality assurance continues to set a benchmark for excellence in the pharmaceutical industry. As PCHPL embarks on its journey towards even greater heights, its steadfast dedication to delivering superior healthcare solutions remains resolute, ensuring a brighter and healthier future for all.
Disclaimer: This is a featured content
Read Exclusive COVID-19 Coronavirus News updates, at MyNation.